Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

ClinicalTrials.gov ID: NCT02436668

Public ClinicalTrials.gov record NCT02436668. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.

Study identification

NCT ID
NCT02436668
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pharmacyclics LLC.
Industry
Enrollment
430 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2015 (Type not available)
Primary completion
Oct 2018 (Actual)
Completion
Apr 25, 2019 (Actual)
Last update posted
Dec 30, 2020

2015 – 2019

United States locations

U.S. sites
28
U.S. states
19
U.S. cities
27
Facility City State ZIP Site status
Oncology Specialties, PC; Clearview Cancer Institute Huntsville Alabama 35805 —
Arizona Center for Cancer Care Avondale Arizona 85323 —
St. Mary's Medical Center Daly City California 94015 —
Moores UCSD Cancer Center La Jolla California 92093 —
Cedars Sinai Medical Center Los Angeles California 90048 —
Norwalk Hospital Norwalk Connecticut 06856 —
Eastern Connecticut Hematology/Oncology Assoc. Norwich Connecticut 06360 —
Bethesda Memorial Hospital Boynton Beach Florida 33425 —
Florida Hospital Tampa Tampa Florida 33613 —
University Cancer & Blood Center, LLC Athens Georgia 30607 —
Northwest Georgia Oncology Centers, PC Marietta Georgia 30060 —
Ingalls Memorial Hospital Cancer Research Center Harvey Illinois 64026 —
Joliet Oncology-Hematology Associates, LTD Joliet Illinois 60435 —
Investigative Clinical Research of Indiana Indianapolis Indiana 46260 —
Mary Bird Perkins Cancer Center Baton Rouge Louisiana 70809 —
Our Lady of the Lake Physician Group Baton Rouge Louisiana 70809 —
Center for Cancer and Blood Disorders Bethesda Maryland 20817 —
Berkshire Hematology Oncology Services at Berkshire Medical Center Cancer and Infusion Center Pittsfield Massachusetts 01201 —
Saint Joseph Mercy Health System Chelsea Michigan 48118 —
Sparrow Regional Cancer Center Lansing Michigan 48912 —
Nebraska Medicine - Peggy D. Cowdery Patient Care Center Omaha Nebraska 68198 —
The Presbyterian Hospital Charlotte North Carolina 28204 —
University of Cincinnati Medical Center Cincinnati Ohio 45267 —
Penn State University Milton S. Hershey Medical Center Hershey Pennsylvania 17033 —
Gibbs Cancer Center Spartanburg South Carolina 29303 —
Scott & White Memorial Hospital Temple Texas 76508 —
MultiCare Health System Institute for Research and Innovation Tacoma Washington 98405 —
Wenatchee Valley Hospital & Clinics Wenatchee Washington 98801 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02436668, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 30, 2020 · Synced Sep 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02436668 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →